

Supplemental Materials

Note: Models including dummy codes for race or ethnicity were not specified, as the frequencies of each non-white identity were so low – out of a total of 103 volunteers for the 23-27 mg analysis, Asian n = 2, unknown = 9, and Hispanic = 2.

Table SA. Multivariate regression analysis results for participants who received 23 to 27 mg (inclusive) psilocybin ($n = 103$) including BMI instead of weight, demonstrating no statistically significant relationships between psilocybin subjective effects and demographic variables.

	Estimate	Std.Err	z-value	p-value
MEQ30 total				
age	-0.002	0.002	-0.898	0.369
race	-0.062	0.067	-0.916	0.360
sex	-0.029	0.046	-0.638	0.523
BMI	0.005	0.007	0.705	0.481
CEQ total				
age	-0.001	0.001	-0.915	0.360
race	0.039	0.052	0.751	0.452
sex	-0.077	0.036	-2.172	0.030
BMI	0.006	0.005	1.130	0.258
Intensity				
age	-0.007	0.008	-0.944	0.345
race	0.075	0.293	0.257	0.797
sex	-0.221	0.200	-1.108	0.268
BMI	0.024	0.030	0.817	0.414

Note: MEQ30 = Mystical Experience Questionnaire; CEQ = Challenging Experience Questionnaire.

Table SB. Multivariate regression analysis results for participants who received 23 to 27 mg (inclusive) psilocybin ($n = 103$) including dummy codes for study. No studies showed statistically significant relationships between psilocybin subjective effects and demographic variables.

	Estimate	Std.Err	z-value	p-value
MEQ30 total				
age	0.000	0.002	0.207	0.836
race	0.011	0.079	0.140	0.888
sex	-0.022	0.045	-0.482	0.630
weight (kg)	0.010	0.017	0.572	0.567
Griffiths et al., 2011	-0.058	0.134	-0.436	0.663
Griffiths et al., 2016	-0.248	0.132	-1.881	0.060
Johnson et al., 2014	-0.315	0.122	-2.588	0.010
Griffiths et al., 2018	-0.107	0.114	-0.939	0.348
NCT02145091	-0.161	0.120	-1.342	0.180
Carbonaro et al., 2018	-0.150	0.137	-1.094	0.274
NCT02243813	-0.087	0.150	-0.583	0.560
Davis et al., 2020	-0.347	0.165	-2.102	0.036
Barrett et al., 2020	-0.098	0.150	-0.652	0.514
CEQ total				
age	-0.002	0.002	-1.620	0.105
race	0.002	0.064	0.024	0.981
sex	-0.079	0.036	-2.179	0.029
weight (kg)	0.002	0.014	0.138	0.890
Griffiths et al., 2011	0.165	0.108	1.529	0.126
Griffiths et al., 2016	0.077	0.106	0.727	0.467
Johnson et al., 2014	0.102	0.098	1.039	0.299
Griffiths et al., 2018	0.054	0.092	0.592	0.554
NCT02145091	0.044	0.096	0.459	0.646
Carbonaro et al., 2018	-0.079	0.110	-0.714	0.475
NCT02243813	0.233	0.121	1.936	0.053
Davis et al., 2020	0.162	0.133	1.221	0.222
Barrett et al., 2020	0.029	0.121	0.236	0.813
Intensity				
age	-0.001	0.008	-0.172	0.864
race	0.244	0.337	0.682	0.495
sex	-0.148	0.203	-0.728	0.466
weight (kg)	0.009	0.078	0.112	0.911
Griffiths et al., 2011	0.173	0.604	0.287	0.774
Griffiths et al., 2016	-0.703	0.595	-1.182	0.237
Johnson et al., 2014	-0.845	0.547	-1.544	0.123
Griffiths et al., 2018	-0.397	0.515	-0.771	0.440
NCT02145091	-0.030	0.540	-0.056	0.955
Carbonaro et al., 2018	-0.122	0.616	-0.197	0.844
NCT02243813	-0.380	0.675	-0.563	0.573
Davis et al., 2020	-1.044	0.744	-1.403	0.161
Barrett et al., 2020	-0.472	0.676	-0.698	0.485

Note: MEQ30 = Mystical Experience Questionnaire; CEQ = Challenging Experience Questionnaire. The Griffiths et al., 2006 study is the reference category. NCT02145091 is a study in meditation practitioners with a long-term daily practice. NCT02243813 is a study in religious professionals.

Table SC. Multivariate regression analysis results for participants who received 20 mg/70 kg psilocybin ($n = 123$) including dummy codes for study. One study showed a statistically significant relationship between psilocybin subjective effects and demographic variables.

	Estimate	Std.Err	z-value	p-value
MEQ30 total				
age	-0.002	0.002	-0.947	0.344
race	0.036	0.069	0.518	0.604
sex	-0.030	0.052	-0.583	0.560
adjusted dose (mg)	0.007	0.007	1.065	0.287
Johnson et al., 2014	-0.128	0.080	-1.601	0.109
Griffiths et al., 2018	0.002	0.064	0.025	0.980
Carbonaro et al., 2018	-0.189	0.082	-2.294	0.022
NCT02243813	0.057	0.085	0.671	0.503
Davis et al., 2020	-0.106	0.099	-1.076	0.282
CEQ total				
age	-0.003	0.001	-1.817	0.069
race	0.039	0.049	0.787	0.431
sex	-0.068	0.037	-1.846	0.065
adjusted dose (mg)	0.005	0.005	1.044	0.296
Johnson et al., 2014	0.011	0.057	0.199	0.843
Griffiths et al., 2018	-0.038	0.045	-0.831	0.406
Carbonaro et al., 2018	-0.188	0.058	-3.227	0.001
NCT02243813	-0.066	0.060	-1.095	0.274
Davis et al., 2020	0.024	0.070	0.339	0.735
Intensity				
age	-0.009	0.008	-1.188	0.235
race	0.434	0.263	1.650	0.099
sex	-0.162	0.198	-0.817	0.414
adjusted dose (mg)	0.021	0.026	0.808	0.419
Johnson et al., 2014	-0.303	0.305	-0.993	0.321
Griffiths et al., 2018	-0.126	0.244	-0.518	0.605
Carbonaro et al., 2018	0.541	0.314	-1.722	0.085
NCT02243813	-0.255	0.322	-0.792	0.428
Davis et al., 2020	-0.320	0.376	-0.850	0.395

Note: MEQ30 = Mystical Experience Questionnaire; CEQ = Challenging Experience Questionnaire. The Griffiths et al., 2011 study is the reference category. NCT02243813 is a study of psilocybin in religious professionals. Statistically significant effects after Bonferroni correction are indicated in bold.

Table SD. Multivariate regression analysis results for participants who received 30 mg/70 kg psilocybin ($n = 193$) including dummy codes for study. One study showed a statistically significant relationship between psilocybin subjective effects and demographic variables.

	Estimate	Std.Err	z-value	p-value
MEQ30 total				
age	-0.003	0.002	-0.947	0.344
race	0.001	0.069	0.518	0.604
sex	0.011	0.052	-0.583	0.560
adjusted dose (mg)	0.001	0.007	1.065	0.287
Griffiths et al., 2011	-0.012	0.080	-1.601	0.109
Johnson et al., 2014	-0.118	0.080	-1.601	0.109
Griffiths et al., 2018	-0.092	0.064	0.025	0.980
Carbonaro et al., 2018	-0.196	0.082	-2.294	0.022
NCT02243813	-0.114	0.085	0.671	0.503
Davis et al., 2020	-0.003	0.099	-1.076	0.282
CEQ total				
age	-0.003	0.002	-1.893	0.058
race	0.002	0.052	0.025	0.980
sex	0.000	0.039	0.276	0.783
adjusted dose (mg)	0.001	0.003	0.263	0.792
Griffiths et al., 2011	0.019	0.072	-0.162	0.871
Johnson et al., 2014	-0.028	0.062	-1.904	0.057
Griffiths et al., 2018	-0.064	0.053	-1.728	0.084
Carbonaro et al., 2018	-0.212	0.079	-2.487	0.013
NCT02243813	-0.164	0.094	-1.222	0.222
Davis et al., 2020	0.063	0.107	-0.027	0.979
Intensity				
age	-0.009	0.001	-2.519	0.012
race	0.434	0.036	0.042	0.967
sex	-0.162	0.027	-0.016	0.987
adjusted dose (mg)	0.021	0.002	0.400	0.689
Griffiths et al., 2011	-0.128	0.050	0.379	0.705
Johnson et al., 2014	-0.303	0.043	-0.660	0.509
Griffiths et al., 2018	-0.126	0.037	-1.755	0.079
Carbonaro et al., 2018	0.541	0.055	-3.886	0.000
NCT02243813	-0.255	0.065	-2.536	0.011
Davis et al., 2020	-0.320	0.074	0.848	0.396

Note: MEQ30 = Mystical Experience Questionnaire; CEQ = Challenging Experience Questionnaire. The Griffiths et al., 2006 study is the reference category. NCT02243813 is a study of psilocybin in religious professionals. Statistically significant effects after Bonferroni correction are indicated in bold.